Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
- PMID: 39727692
- PMCID: PMC11675061
- DOI: 10.3390/curroncol31120569
Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
Abstract
(1) Background: To make recommendations on the most effective therapy options for Ductal Carcinoma of the Breast (DCIS) patients; (2) Methods: MEDLINE, EMBASE, Cochrane Library, PROSPERO databases, and main relevant guideline websites were searched. Draft versions of the guideline went through formal internal and external reviews, with a final approval by the Program in Evidence Based Care and the DCIS Expert Panel. The Grading of Recommendations, Assessment, Development, and Evaluation approach was followed; (3) Results: Based on the current evidence from the systematic review and this guideline authors' clinical opinions, initial draft recommendations were developed to improve the management of patients with DCIS. After a comprehensive internal and external review process, ten recommendations and 27 qualifying statements were eventually made. This guideline includes recommendations for the primary treatment of DCIS with surgical treatment and/or radiation therapy and the management of DCIS after primary treatment for patients with DCIS, including DCIS with microinvasion (<1 mm through the duct); (4) Conclusions: The current guideline was created after a systematic review and a comprehensive internal and external review process. We believe this guideline provides valuable insights that will be useful in clinical decision making for health providers.
Keywords: Ductal Carcinoma in Situ; endocrine therapy; guideline; radiation therapy; surgery.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent.Clin Oncol (R Coll Radiol). 2024 Apr;36(4):243-253. doi: 10.1016/j.clon.2024.01.012. Epub 2024 Jan 20. Clin Oncol (R Coll Radiol). 2024. PMID: 38336503
-
Evidence map of ductal carcinoma in situ management options.Menopause. 2019 Nov;26(11):1250-1258. doi: 10.1097/GME.0000000000001397. Menopause. 2019. PMID: 31567868
-
Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?Surg Oncol Clin N Am. 2018 Jan;27(1):69-80. doi: 10.1016/j.soc.2017.08.002. Surg Oncol Clin N Am. 2018. PMID: 29132566 Review.
-
Ductal Carcinoma In Situ - Quo Vadis?Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S5-S6. Chirurgia (Bucur). 2021. PMID: 34967322 Review.
-
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).NIH Consens State Sci Statements. 2009 Sep 24;26(2):1-27. NIH Consens State Sci Statements. 2009. PMID: 19784089
References
-
- Shelley W., McCready D., Holloway C., Trudeau M., Sinclair S., Breast Cancer Disease Site Group Management of Ductal Carcinoma In Situ of the Breast; Toronto (ON): Cancer Care Ontario; 19 September 2006 [In review Jan 2014]. Program in Evidence-based Care EvidenceBased Series No.: 1–10 Version 2.2006 IN REVIEW. [(accessed on 29 October 2024)]. Available online: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=02deec396....
-
- Browman G.P., Newman T.E., Mohide E.A., Graham I.D., Levine M.N., Pritchard K.I., Evans W.K., Maroun J.A., Hodson D.I., Carey M.S., et al. Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback. J. Clin. Oncol. 1998;16:1226–1231. doi: 10.1200/JCO.1998.16.3.1226. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical